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While the etiology is unknown, serotonin and glutamate G protein-coupled receptors (GPCR) 
neurotransmission dysfunctionality is characteristic of schizophrenia. Previous findings 
demonstrated that the serotonin 5-hydroxytryptamine 2A (5-HT2A) receptor and the metabotropic 
glutamate 2 (mGlu2) receptor assemble into a heteromeric complex; however, little is known of 
the complete structural interface of the heteromer. Through a mutational-based approach, 
previous research identified Transmembrane domain 4 (TM4) as being responsible for mediating 
heteromerization in mGlu2 before determining the particular amino acids responsible for the 
interface. A similar technique was used in this investigation to determine which component of 5-
HT2A is responsible for the heterodimeric interface. Here, I identified four residues at the N-
terminal of transmembrane domain four essential for the 5-HT2A receptor to form a GPCR 
heteromer with the mGlu2 receptor in HEK-293 cells. Substitution of these residues 
(phenylalanine 4.43, leucine 4.44, isoleucine 4.47, and alanine 4.48) leads to a significant 
reduction of 5-HT2A·mGlu2 receptor complex formation. This finding offers potential targets for 
future photo-crosslinking investigations to identify the particular residues within the 5-HT2A 





Chapter 1: Introduction 
Schizophrenia 
Schizophrenia affects 0.3-1.1% of the population and is a persistent, severe, and debilitating 
mental illness with long-term consequences for patients and their families (Howes and Kapur, 
2009). Life expectancy may be reduced by as much as 15 years in schizophrenia patients, with 
morbidity being considerably more significant than with illnesses such as pulmonary and 
cardiovascular sickness (Saha et al., 2007; Olfson, 2015). A significant contributor to this loss of 
life is suicide, with studies estimating individuals with schizophrenia have a lifetime suicide risk 
of 5-10%. (Hor, 2010; Freedman, 2003). However, mortality should not be the sole measure of 
severity of a disease, as it is not representative of the hardships faced by an individual with a 
given condition. Disability-adjusted life years (DALY) can be used instead to provide a metric 
that quantifies the overall burden of illnesses. In conjunction with the World Health Organization 
and the World Bank, DALY was pioneered by Christopher, Murray, and Lopez, resulting in the 
first Global Burden of Disease (GBD) study in 1990. According to the most recent GBD study in 
2016, schizophrenia accounts for 1.7% of the total DALYs globally and carries the highest 
disability weight of all disorders in the GBD (Charlson et al., 2018; Salomon et al., 2015). 
Economically, schizophrenia was estimated to cost the United States $155 billion in 2013 
through both direct and indirect healthcare costs, totaling $44,773 per individual patient based on 
a prevalence of 1.0%. When compared to major depressive disorder (MDD), which affects 8.1% 
of the United States population and indirect costs $210.5 billion ($4,071.8 per MDD patient), the 
severe economic burden schizophrenia imposes becomes more evident (Greenberg et al., 2015; 




Schizophrenia, which usually develops during adolescence or early adulthood, can present itself 
with a wide variety of symptoms, the hallmarks being changes in perception, thought, and 
behavior. (Owen et al., 2016). 
The DSM-5 diagnostic criteria for schizophrenia include hallucinations (i.e., sensory perceptions 
in the absence of concurrent sensory stimuli), delusions (i.e., beliefs firmly maintained despite 
significant evidence of them being not true), disorganized speech and behavior (e.g., grossly 
disorganized, frequent derailment or incoherence), and negative symptoms (characterized by loss 
or deficits of features that are present in healthy individuals) (American Psychiatric Association, 
2013). Disability often results from both a combination of negative symptoms and cognitive 
symptoms (e.g., learning and attention disorders). In addition, relapse may occur because of 
positive symptoms (characterized by an excess or distortion of normal function), such as 
suspiciousness, delusions, and hallucinations (Crismon et al,. 2014; Patel et al,. 2014 ).  
While the etiology of schizophrenia is unknown, it has been demonstrated to involve a variety of 
structural and neurochemical dysfunctions in multiple brain regions (Ripke et al., 2013), of 
which abnormalities in neurotransmitter systems have been proposed to contribute significantly 
(Brish et al., 2014).  
Overactive dysregulation in the dopaminergic neurotransmitter (DA) system has been the 
predominant pathophysiological hypothesis of schizophrenia. This stemmed from two 
observations: 1) first-generation “typical” antidopaminergic antipsychotics primarily as D2 
antagonists 2) indirect D2 agonists (amphetamine, phencyclidine, etc.,) induce psychotomimetic 
effects or exacerbate schizophrenic symptoms by increasing dopamine activity in the subcortical 




the frontal cortex, which observed increases in D2 receptor expression and D2 mRNA levels, 
with increased activity in the mesolimbic pathway (Davis et al., 1991; Abi-Dargham et al., 2000; 
Tallerico et al., 2001).  
The roles of other neurotransmitters such as glutamate (Glu) and serotonin (5-HT) in the 
neuropathology of schizophrenia have started to gain particular attention as being the primary 
target of second-generation antipsychotics (Miyamoto et al., 2005; Conn et al., 2009). 
Furthermore, the psychotomimetic effects of drugs that antagonize the glutamate and serotonin 
signal recapitulate schizophrenia ethology to a much more accurate extent than drugs that simply 
stimulate dopamine signaling (Kapur et al., 2002; Halberstadt et al., 2011). 
Many neurotransmitters involved in schizophrenia act through metabotropic G protein-coupled 
receptors (GPCRs). Serotonin, dopamine, and glutamate are traditionally recognized as 
molecular targets in this investigation (Patil S et al., 2007; Kwan C et al., 2021). 
General GPCR characteristics 
G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors in the 
human genome that function to mediate slow synaptic transmission by modulating intracellular 
signal transduction, through which they regulate an incredible range of physiological processes 
ranging from cell growth to neurotransmission (Ji et al., 1998; Levoye A et al., 2006; 
Grundmann et al., 2018). 
GPCRs share a common structure comprised of a single polypeptide chain with seven 
transmembrane (TM) α-helix domains, an extracellular amino-terminal, an intracellular 




GPCRs are heterotrimeric comprised of an: α-subunit, β-subunit, and γ-subunit. By interacting 
with other membrane proteins involved in signal transduction, these subunits relay messages 
within the cell (Rosenbaum et al., 2009). While sharing distinct structural characteristics, GPCRs 
have been classified into five major families according to phylogenetic criteria: Family A 
(rhodopsin-like), Family B (secretin receptor family), Family C (metabotropic glutamate 
receptors), Adhesion, and Frizzled/Taste2. Sequence homology within these families is at least 
40%, with the greatest homology at the transmembrane domain. (Vassilatis et al., 2003; 
Bjarnadóttir et al., 2006) 
GPCRs can further be categorized by downstream signaling pathways depending on the α 
subunit: Gi/o, Gs/olf, Gq/11, and G12/13. As the name suggests, in response to ligand binding, GPCRs 
activate heterotrimeric guanine nucleotide-binding proteins (G proteins), stimulation of which 
results in a dissociation of the Gα subunit from the Gβγ dimer and allows the subunits to activate 
or inhibit various effectors. Gs/olf (stimulatory) and Gi/o (inhibitory) pathways regulate cAMP-
dependent signaling by either stimulating or inhibiting adenyl cyclase activity. The Gq/11 coupled 
pathway operates via phospholipase C-β enzymes, which hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5- trisphosphate (IP3). Hydrophilic 
IP3 diffuses into the cell and acts as a second messenger to release stored calcium from the 
endoplasmic reticulum lumen into the cytoplasm. Whereas DAG acts as a second messenger that 
activates protein kinase C (PKC). G12/13 stimulates small GTPase downstream signaling 
(Moghaddam et al., 2004; Liu et al., 2021). 
Comprehensive research on GPCRs led to the identification of an orthosteric site for endogenous 
ligand binding as well as several allosteric sites that can modulate response: Positive Allosteric 




central roles in many cellular functions and numerous binding sites, GPCRs are an important 
therapeutic target, with different reports suggesting that between 30 and 40% of FDA-approved 
drugs target GPCRs (Wise et al., 2002; Brink et al., 2004). 
Initially, GPCRs were thought to exist and function as monomeric structural units that couple to 
G-proteins in a 1:1 stoichiometric ratio. (Liang Y et al., 2017) This model is supported by 
evidence that purified monomeric β2-adrenoreceptor (Family A) reconstitutes in a phospholipid 
bilayer is sufficient for fully functional G protein activation (Whorton et al., 2007; Kuszak et al., 
2009).  
However, over the last decade, the notion that these receptors function exclusively as monomeric 
proteins has been challenged, with indications that GPCRs can exist and function as dimers or 
even higher-order oligomers. Investigation into Family A, D2 receptors indicated the receptor 
requires two structural units to one G-protein to be maximally activated by a single bound ligand 
(Han et al., 2009). Additional evidence suggests class C metabotropic Glutamate (mGlu) and 
GABA receptors act as obligate homodimers, suggesting dimerization is crucial for receptor 
function (Kniazeff et al., 2011). 
GPCRs may also undergo heterodimerization. Initial evidence for this model came from studies 
of the α2-adrenoreceptor and M3 muscarinic receptor in which two mutant chimeras were 
generated with TM-6 and TM-7 exchanged between α2C and M3. This revealed that only when 
co-transfecting the α2/M3 and M3/α2 chimeras resulted in stimulation, suggesting the two 
receptors are intricately connected, and the presence of all transmembrane domains was 
necessary and sufficient for signaling, regardless of which specific receptor they were inserted in 




Perhaps the most eloquent example of heterodimerization is the interaction between GABAB-R1 
and GABAB-R2 subunits in forming a fully functional GABAB (γ-aminobutyric acid type B) 
receptor. Functional membrane receptors were created by co-expression of recombinant 
GABAB-R1 and GABAB-R2 plasmids but not by expressing each recombinant plasmid alone. 
Further studies exploring this model revealed GABAB-R1 appears to determine the 
pharmacological properties of the receptor, while GABAB-R2 is essential for the proper 
expression of GABAB-R1 on the plasma membrane. (Filippov et al., 2000; Jones et al., 2000) 
Heterodimerization involving two fully functional GPCRs from distinct families has also been 
well established. κ and δ opiate receptors have been shown to form a fully functional 
heterocomplex receptor that exhibits distinct functional and ligand-binding characteristics 
distinct from those of either receptor alone (Jordan & Devi, 1999). 5-HT2A and D2 have also 
been shown to form a functional heterocomplex with ligands conveying different effects on 
downstream signaling depending on whether homo- or hetero-dimers are present. (Łukasiewicz 
et al., 2010) Additionally, Family A 5-HT2A and Family C mGlu2 receptors have been shown to 
form a functional heterocomplex in the mammalian brain and tissue culture preparations. 
(González-Maeso et al., 2008; Rives et al., 2009; Moreno et al., 2012).  
There are several ways that a heterocomplex interaction can be assessed. Co-
immunoprecipitation (Co-IP) assays are robust measures to determine whether two proteins 
interact. Co-IP is performed by binding one of the proteins of interest with a magnetic bead, then 
washing away all proteins that are not bound to the antibody-bead-protein complex, followed by 
immunoblot probing for the second protein of interest. If the two proteins are part of the same 
protein complex, then there would be an immunoreactive signal detected for the protein that was 




methods to address GPCR complex formation, including Förster (Fluorescence) Resonance 
Energy Transfer (FRET) and Bioluminescence Resonance Energy Transfer (BRET). FRET is a 
technique where after excitation with a laser, an excited donor molecule (e.g., cyan fluorescence 
protein) transfers resonance energy to an acceptor molecule (e.g., yellow fluorescence protein), 
producing a highly distance-dependent fluorescence. Therefore, this can accurately measure the 
molecular proximity of two proteins at angstrom distances (10-100 Å) (Sekar et al., 2003). 
BRET is a very similar technique to FRET; however, the resonance energy transfer is not 
between two fluorescent proteins but rather between a bioluminescent donor and a fluorescent 
acceptor and therefore does not require an excitation source (Dimri et al., 2016). 
The 5-HT2A·mGlu2 Heteromeric Receptor Complex 
Abnormalities in the serotonin and glutaminergic system have been observed in schizophrenia 
patients compared to neuropsychiatric healthy control subjects. Postmortem and neuroimaging 
studies suggest an increase in Gq/11-coupled 5-HT2A receptor density with concurrent decreases in 
Gi/o-coupled mGlu2/3 receptor density and treatment with second-generation antipsychotic drugs 
decreases density to control levels (Gonzalez-Maeso et al., 2008). This has similarly been 
verified in a rodent model where chronic treatment with second-generation antipsychotics, 
clozapine and risperidone, downregulated 5-HT2A cortical neurons. (Gonzalez-Maeso et al., 
2008; Kurita et al., 2012). Additionally, rodent studies revealed that the administration of classic 
serotonergic psychedelics in mGlu2 -/- knock-out mice eliminated the hallucinogenic-specific 
signaling component, suggesting this pattern of 5-HT2A, mGlu2 density may predispose 




Previous findings have also demonstrated cross-talk between the Gq/11-coupled 5-HT2A and the 
Gi/o-coupled mGlu2 receptors, showing they form a heteromeric complex via which the 5-
HT2A·mGlu2 complex incorporates both serotonin and glutamate signaling to modulate 
downstream signaling and behavioral changes (Moreno, 2016). Further studies have indicated 
that in response to endogenous ligands (glutamate and serotonin), the 5-HT2A·mGlu2 
heteromeric complex functions to establish a Gi/o-Gq/11 balance, which is believed to underlie the 
therapeutic action of mGlu2 activators and 5-HT2A antagonists. Classic psychedelics such as 
LSD, Mescaline, and Psylocibin, have been shown to shift the signaling balance towards a more 
psychosis-like condition, while on the other hand, second-generation antipsychotics have been 
shown to recover the Gi/o/Gq/11 imbalance (Fribourg et al., 2011). 
This heteromeric complex allows for a plethora of therapeutic targets to allow for more 
deliberate modulation intracellular signal, rather than each individual GPCRs (Wootten et al., 
2018). 
Mapping the Heteromeric Interface of 5HT2A-mGlu2 
Within the 5-HT2A·mGlu2 complex, the structural mechanisms responsible for forming the 
oligomer are poorly understood, as is/are the molecular mechanism(s) responsible for cross-talk. 
In the investigation into the mechanism by which 5-HT2A·mGlu2 heterocomplex modulates 
downstream signaling, the structure of the heteromeric interface must be considered. Several 
studies have used a mutational-based approach to examine whether a direct mechanism 
contributes to cortical cross-talk between the two receptor systems (Moreno et al., 2012) 
Co-immunoprecipitation assays of human brain cortex samples and transfected HEK-293 cells 




protein complex (Gonzalez-Maeso et al., 2008). Due to the sequence homology between 
mGlu2/3, mutant chimeras with non-homologous amino acid residues of mGlu3 were inserted 
into mGlu2 in order to disrupt the heteromeric assembly. Through this method, researchers 
identified three residues at the intracellular end of TM4 (Alaine 4.40, Alanine 4.44, and Alanine 
4.48), which are necessary to form the 5-HT2A·mGlu2 receptor heterocomplex. Additionally, 
when the TM4 residues of mGlu2 were inserted into the mGlu3, it was sufficient for signaling 
cross-talk to occur (Moreno et al., 2012). 
As there is similar discrimination found between the 5-HT2A and 5-HT2C (which does not form a 
protein complex with mGlu2), additional investigations utilizing a similar mutational chimeric 
method to the one described above indicated the TM4 domain of 5-HT2A is necessary for the 
heterocomplex to form. (Moreno et al., 2016.)    
Objective 
With abundant research highlighting the biological relevance of the 5-HT2A·mGlu2 
heterocomplex in modulating signaling, the complete structural interface between the two 
GPCRs remains unknown. 
While the residues in mGlu2 responsible for dimerization have been identified, the residues in 5-
HT2A remain unidentified, having only been limited down to the TM4 domain. I hypothesize that 
the residues in the N-terminal half of 5-HT2A are responsible for mediating the formation of a 
heterocomplex with mGlu2.  
This was assessed using a heterologous expression system in human embryonic kidney cells 




TM4 of 5-HT2A closest to the N terminus (5-HT2A-TM4ΔNF) was co-expressed with mGlu2 to 
attempt to disrupt the binding interface of the heteromer.  
The four 5-HT2A residues mutated (phenylalanine 4.43, leucine 4.44, isoleucine 4.47, and alanine 
4.48) were chosen to start this investigation because these residues i) are different between 5-
HT2A and 5-HT2C, and ii) are located facing towards the lipid bilayer according to the recent 
crystal structure of the 5-HT2A (Kimura et al., 2019) 
Disruption of the heterocomplex was evaluated using a co-immunoprecipitation followed by 
immunoblotting. Further characterization of the mutant chimera was also performed to confirm 
level of expression, cellular localization and function homology to WT 5-HT2A. 
Chapter 2: Research Methods 
Plasmid Preparation, Amplification, and Sequencing of Constructs  
The constructs pcDNA3.1-c-Myc-5-HT2A-mCherry and pcDNA3.1-HA-mGluR2-mCitrine, 
described previously (Moreno et al., 2016), and 5-HT2A-TM4ΔNF were obtained (Kareem, 
2020). The primer used for sequencing of Mutant construct (5-HT2A-TM4ΔNF) was: 5’-AGC 
TGA TAT GCT GCT GGG TT -3’. Following sequence verification, constructs were 
transformed into XL1-Blue Supercompetent Cells (Agilent Technologies; CN: 200236) before 
purification and amplification by Plasmid Maxi Prep (QIAGEN). 
Cell culture 
Human Embryonic Kidney (HEK)-293 cells were used for transfection and cultured in a 5% CO2 




glutamine, sodium pyruvate) supplemented with 10% (v/v) dialyzed fetal bovine serum (dFBS) 
(Thermo Fischer Scientific; CN: 26400044) and 1% (v/v) Penicillin-Streptomycin (Thermo 
Fischer Scientific; CN: 15140122) (except immediately prior to transfection, as noted below). 
Cells underwent passages every 2-3 days, using fresh Medium A in a ratio between 1:8 and 1:12, 
to keep the cells in their exponential growth phase and never passaged higher than 20 times. 
Transient Transfection of HEK 293 cells 
48hr before transfection, HEK-293 cells were split and cultured in DMEM supplemented with 
10% (v/v) dFBS only. All Transient transfections were conducted with Lipofectamine 3000 
(Invitrogen; CN: L3000001) using a Lipofectamine 3000 to plasmid ratio of 1:1.5 and performed 
according to the manufacturer’s recommendations. A total of 6 μg/plate of plasmid DNA was 
used in each single transfection. This includes the individual transfection of the constructs, c-
Myc-5-HT2A-mCherry, and c-Myc-5-HT2A-TM4ΔNF-mCherry. A total of 12 μg of DNA was 
used in each co-transfection with a plasmid ratio of (1:2), 4 μg of which were vector, 5-
HT2A receptor, or mutant 5-HT2A receptor DNA and 8 μg of which was DNA construct HA-
mGluR2-mCitrine. This includes co-transfection of constructs c-Myc-5-HT2A-TM4ΔNF-
mCherry with HA-mGluR2-mCitrine, and c-Myc-5-HT2A-mCherry with HA-mGluR2-mCitrine. 
24hr after transfection, media was removed and replaced with DMEM supplemented with 10% 
(v/v) dFBS and 1% (v/v) Penicillin-Streptomycin, for an additional 24hr before harvesting. 
Cell Membrane Preparation 
48 Hours following transfection, cells were harvested with Dulbecco’s Phosphate-Buffered 
Saline, 1X without calcium and magnesium (DPBS) (Corning; CN: 21031CV). The resulting cell 




used to homogenize the cell pellet (50 ups/downs) in 10ml Tris-HCl 1x (50 mM Tris-HCl, pH 
7.4). Homogenized tissue was spun for 5 min at 1,000 × g (4°C) and the pellet was discarded. 
The supernatant was spun for 15 min at 40,000 × g. Subsequent pellet was washed with 500 μl 
Tris-HCl and spun again for 15 min at 40,000 × g. The pellet was resuspended in 500μl of Tris-
HCl and transferred to a 1.7 ml Eppendorf tube, then spun at 18,000 × g in a microcentrifuge for 
15 min at 4°C. The Tris-HCl 1x was removed, and the pellet was either used or stored at −80°C 
until use. 
Co-immunoprecipitation 
Co-immunoprecipitation was conducted using 600μg of prepared cell membrane. Protein Assay 
(Bio-Rad; CN: #5000006) was performed to normalize the amount of protein. Membranes were 
resuspended with 500μl RIPA buffer (50 mM HEPES, 150 mM NaCl, 5mM EDTA, and Mini 
EDTA-free Protease Inhibitor Cocktail tablet (Roche Applied Sciences; CN: 04693159001), pH 
7.4) and allowed to solubilize with 500μl Solubilization buffer (RIPA buffer supplemented with 
1% SDS and 2% Triton X-100 (Fischer Scientific; CN: BP151-500)) by incubation on a rotating 
mixer at 4 °C for 1hr. Cells were incubated on a rotating mixer with Protein A/G PLUS-Agarose 
immunoprecipitation beads (Santa Cruz Biotechnology; CN: sc-2003) at 4 °C for 30 minutes to 
account for non-specific binding. 100μl of the cell lysates was saved for Total Protein control, 
and the remainder was then incubated with immunoprecipitation beads conjugated to c-HA-Tag-
Mouse Ab (diluted 1:1000; Cell Signaling Technology; CN: 3724) at 4 °C for 18 hours. The 
beads were washed at 4 °C three times in RIPA buffer. Immunoprecipitated proteins were then 






Samples were mixed with 5μl 5x Laemmli buffer and heated for 5 min at 97 °C. Proteins were 
resolved by 12% SDS-PAGE and transferred to nitrocellulose membranes by electroblotting. 
Nitrocellulose blots were washed with TBST (150 mM NaCl, 50 mM Tris-Cl, and 0.1% Tween 
20, pH 7.6) before incubating the membrane in Blocking Buffer (TBST, 2.5% nonfat dry milk, 
0.5% BSA) for 1hr at room temperature. Nitrocellulose blots were then incubated (overnight at 
4° C) with c-myc-Tag-Mouse Ab (diluted 1:1000; Cell Signaling Technology; CN: 9B11). 
Following six washes with TBST, blots were incubated with Anti-Mouse IgG Horseradish 
peroxidase (HRP) conjugated secondary Ab (1:5000; ACCURATE Chemical Science Corp.) 
After incubation, blots were washed six more times with TBST for 30 minutes and developed 
using enhanced chemiluminescence detection (SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate; Thermo Fischer Scientific) in accordance with manufacture 
instructions. Immunoreactive bands were analyzed using ChemiDoc Imaging System and Image 
Lab (Bio-Rad Laboratories). Final data of Co-immunoprecipitation are expressed as a ratio of the 
relative density of the 250kDa band to its respective 250 kDa total protein band. Final data for 
characterization of immunoblot signal is expressed as the 250 kDa was normalized to β-actin. 
Observed differences were considered statistically significant if P-values were below 0.05. 
Radioligand binding 
Saturation binding assays were performed with the 32μg prepared cell membranes and 
[3H]ketanserin (22.8 Ci/mmol; PerkinElmer; CN: NET1233), then incubated in Tris-HCl for 1hr 
at 42°C. The following [3H]ketanserin concentrations were used: 10 nM, 5 nM, 2.5 nM, 1.0 nM, 




at each concentration were measured). Non-specific binding was determined by incubating the 
reactions with 100μM methysergide (Tocris; CN: 1064); two samples were pooled for each 
assay. Protein Assay (Bio-Rad; CN: #5000006) was performed to normalize the amount of 
protein in each assay. Reactions were harvested by vacuum filtration through Glass fiber 
Filtermat A (PerkinElmer) (3× 50 mM Tris-HCl, pH 7.4) and counted by liquid scintillation 
using a PerkinElmer 2450 MicroBeta2. Data analyses were performed using Microsoft Excel and 
GraphPad Prism v8.0 (GraphPad software, San Diego, CA, USA). KD and Bmax were determined 




[Ca2+]i Mobilization Assay 
Functional signaling was assessed by measuring Ca2+ release in the presence of serotonin 
(100μM, 10μM, 1μM, 100nM, 10nM, 1nM, 0.1nM, 0nM ) in 5-HT2A-TM4ΔNF or WT 5-HT2A 
cells. The day before the assay, 50,000 (5-HT2A) or 50,000 (5-HT2A-TM4ΔNF) cells/50 μL were 
seeded in poly-D-lysine coated (1mg/ml) 96-well black plates (Greiner 781091). The cells were 
incubated with 50μl 3 μM Fluo 4 Direct (Thermo Fisher Scientific; CN: F10471) in imaging 
solution (5 mM KCl, 0.4 mM KH2PO4, 138 mM NaCl, 0.3 mM Na2HPO4, 2 mM CaCl2, 1 mM 
MgCl2, 6 mM glucose, 20 mM HEPES, pH 7.4) supplemented with pluronic acid (10% solution 
in DMSO) for 1 h at 37˚C, as described in the manufacturer’s instructions. Changes in 
fluorescence due to intracellular Ca2+ mobilization were measured using a FlexStation® plate 
reader (Molecular Devices) with λex 494 nm and λem 525 nm. Baselines were recorded every 2 
s for 30 s. Serotonin was added at 30 s; reading started at 90 s after serotonin transfer, reading 
every 1 s for a total of 180 s. The fluorescence was a measure of intracellular calcium and was 




Functional data was analyzed by nonlinear regression to generate concentration-response curves 
and EC50 values by Prism V8.0 software, (Y=Bottom + (Top-Bottom) / (1 + 10 ^ ((LogEC50-
X)*HillSlope)(GraphPad Software, San Diego, CA, USA).  
Confocal microscopy imagine 
Confocal microscopy imaging was performed on pcDNA3.1-c-Myc-5-HT2A-mCherry and 
pcDNA3.1-c-Myc-5-HT2A-TM4ΔNF-mCherry transfected HEK 293 cells. Samples were fixed in 
pre-cooled 4% paraformaldehyde in 1x PBS for 30 minutes, then washed twice with 1X PBS 
before incubating the membrane in Blocking Buffer (1x PBS, 5% BSA) for 2hr. Cells were then 
stained with 1:10,000 dilution Hoechst 3342 (20mM) (Thermo Fischer Scientific; CN: 62249) 
for 15 minutes, then washed two times in Phosphate-Buffered Saline (137 mM NaCl, 2.7 mM 
KCl, 8 mM Na2HPO4, and 2 mM KH2PO4) (10 minutes for each wash). Coverslips were 
transferred to a microscope slide and mounted (Invitrogen ProLong™ Diamond Antifade 
Mountant) for microscopic fluorescence visualization. Images were acquired using a Zeiss 
LSM710 laser-scanning confocal microscope (Carl Zeiss AG, Jena, Germany) with Airyscan 
(Plan-Apochromat, objective 63×, Numerical Aperture 1.4). The zoom images are digitally 
cropped using the same objective at 2x zoom. Microscopy was performed at the VCU 
Microscopy Facility, supported, in part, by funding from NIH-NCI Cancer Center Support 







Chapter 3: Results 
Sequence alignment 
Sequence analysis was performed to corroborate whether the 5-HT2A-TM4ΔNF chimera was 
mutated to contain 5-HT2C TM4 N-terminal residues. All residues were identified using the 
Ballesteros-Weinstein sequence-based numbering system. This revealed successful replacement 
of WT 5-HT2A residues phenylalanine 4.43, leucine 4.44, isoleucine 4.47, and alanine 4.48 with 
the isoleucine 4.44, methionine 4.55, alanine 4.47, and isoleucine 4.48 found in WT 5-HT2C (Fig 
1). 
 
Characterization by Immunoblot 
To assess whether the c-myc-5-HT2A-TM4ΔNF receptor was expressing itself properly, and 
there was no misfolding, immunoblot assays were performed to test whether the molecular 
weight of c-myc-5-HT2A-TM4ΔNF is equivalent to 5-HT2A. Immunoblot assays were performed 
Figure 1. 5-HT2A-TM4ΔNF sequence homology between 5-HT2A and 5-HT2C in TM4. 
Amino acid sequence alignment of the transmembrane domain 4 (TM4) of Human 5-HT2A, 5-
HT2C, and 5-HT2A-TM4ΔNF receptors. All residues were identified by the sequence-based 
numbering system by Ballesteros-Weinstein. Residues that are different between 5-HT2A and 5-
HT2C in N-terminal TM4 are highlighted in red, with the 5-HT2A-TM4ΔNF mutant sequence 




in membrane lysates of HEK-293 cells transiently transfected with these two constructs. Anti-c-
myc immunoreactivity was detected as a mixture of a 53kDa band and a band of approximately 
250 kDa corresponding to the size anticipated for a 5-HT2A monomer and oligomer, respectively 
(Fig. 2). There was no significant difference seen in c-myc immunoreactivity between the c-myc-











Figure 2 Immunoblot assay.  A) Representative Western blot for 5-HT2A and 5-HT2A-TM4ΔNF. B) 
Histogram of immunoreactivity (after normalization) of 250 kDa 5-HT2A and/or 5-HT2A-TM4ΔNF. 
Normalized to β-actin. Error bars indicate S.E.M., significance determined by unpaired Student’s t-





5-HT2A TM4 N-terminal Residues Role in Mediating Association with mGlu2 
Co-immunoprecipitation was performed using anti-HA antibodies in plasma membrane 
preparations of HEK-293 cells transfected to express the HA-mGlu2 together with the c-myc-
5HT2A-TM4ΔNF receptors. Immunoblot analysis of co-immunoprecipitated material revealed 
anti-c-myc immunoreactivity was detected at ~ 250 kDa band, this corresponding to the size of 
the 5-HT2A oligomer. 
Interestingly, substitution of residues F4.43, L4.44, I4.47, and A4.48, in 5-HT2A with the I4.44, 
M4.55, A4.47, and I4.48 in 5-HT2C (5-HT2A-ΔTM4NF) significantly reduced co-
immunoprecipitation with mGlu2 (n=3 unpaired Student’s t test (t = 4.687, df = 4, P = .009) 
(Fig. 3).  
A) 
Figure 3. Co-immunoprecipitation 5-HT2A-TM4ΔNF + mGlu2. A) Western blots showing 
results of immunoprecipitation with HA-tagged Ab, Wb c-Myc Ab. B) Histogram shows 
average relative densitometric, from three replicates, normalized to the total protein control 
before immunoprecipitation. Error bars indicate S.E.M. significance determined by unpaired 




Functional Characterization of 5-HT2A-TM4ΔNF 
In light of the ΔTM4NF mutation’s apparent role in mediating the heteromeric interface, further 
characterization assays were performed to assess functional homology with 5-HT2A. As noted 
above, 5-HT2A is a Gq/11 coupled GPCR which, when stimulated, produces a transient increase in 
the concentration of intracellular Ca2+. An intracellular calcium mobilization assay performed in 
c-myc-5HT2A-TM4ΔNF transfected HEK-293 cells revealed 5-HT produced a concentration-
dependent increase of signal, corresponding to that observed in 5-HT2A (Fig. 4) (EC50:  5-HT2A -
ΔTM4NF: 5.6 nM; 5-HT2A: 6.9 nM. Emax = 5-HT2A -ΔTM4NF: 98.89; 5-HT2A: 100.2) Analyzed 
by nonlinear regression to generate concentration-response curves and analysis by unpaired 
Student’s t-test showed no significance (P = .997).  As there was no Ca2+ mobilization detected 
in untransfected HEK-293 cells, it can be assumed that the transient increase observed in Fig. 4 









Antagonist radioligand saturation 
5-HT2A -ΔTM4NF and 5-HT2A membrane preparations were subjected to saturation analysis with 
the high-affinity antagonist [3H]ketanserin to determine receptor density. Nonlinear analysis of 
binding fitted to a saturation curve showed no significant difference in KD (binding affinity) or 
Bmax (receptor density) (Bmax: 5-HT2A -ΔTM4NF:  223.0 ± 23.32 fmol/mg; 5-HT2A: 211.3 ± 
27.01 fmol/mg. KD: 5-HT2A -ΔTM4NF: 6.129 ± 1.260 nM; 5-HT2A: 6.784 ± 1.648 nM) (n=3 per 
group). These results further suggest 5-HT2A -ΔTM4NF expresses itself to the same extent as its 
Figure 4. Ca2+ mobilization on transiently transfected HEK-293 cells with Fluo-4. 
Concentration dependent Ca2+ mobilization for serotonin in transiently transfected HEK-293 
cells expressing 5-HT2A-ΔTM4NF or 5-HT2A (50,000 cells/well). All concentration responses 
represent the mean of two independent experiments, each performed in triplicate wells (n = 2). 





wild-type counterpart. It should be noted there was no full saturation observed in these assays, 





Subcellular Localization of 5-HT2A-ΔTM4NF-mcherry 
Finally, subcellular localization of the 5-HT2A -ΔTM4NF construct was investigated. For the 5-
HT2A receptor to be functional, the receptor must be trafficked into the plasma membrane to then 
interact with a ligand to propagate a signal into the cell, therefore any potential changes in 
trafficking due to the 5-HT2C mutations had to be investigated. To allow for easier identification, 
both the WT and mutant 5-HT2A constructs contained a fluorescent c-terminal mCherry tag. 
Hoechst stain was applied to identify the nucleus before fixation. Images acquired through 
confocal fluorescent microscopy (Fig. 6C, 6F) show the cellular distribution of 5-HT2A-
Figure 5. [3H] Ketanserin saturation binding. Binding saturation curves in 5-HT2A wild type 
(red) and 5-HT2A -ΔTM4NF (blue). The binding of radioligand is plotted as a function of 
radioligand concentration. Specific binding was obtained by subtracting non-specific binding 
from total binding. All binding concentrations represent the mean – S.E.M. (n = 3; independent 




ΔTM4NF-mcherry is similar to the WT 5-HT2A-mcherry in HEK-293 s cells. Subcellular 
localization of both receptors is predominantly distributed around the cell in the plasma 
membrane with m-cherry fluorescence also detected within another unidentified subcellular 
compartment(s).  
 
Chapter 4: Discussion 
Although the structural interface of mGlu2 in mediating the heteromeric complex of 5-
HT2A·mGlu2 has been identified, the 5-HT2A heteromerization residues have only been narrowed 
down to the TM4 domain.  This study provides evidence for the involvement of four residues 
Figure 6 Cytochemistry 5-HT2A-TM4ΔNF in HEK-293 cells. Confocal analysis 
highlighting the presence of 5-HT2A-ΔTM4NF-mcherry receptor in transiently transfected 




located at the intracellular end of TM4 within 5-HT2A in its heteromeric assembly with the 
mGlu2 receptor. 
These findings indicate the residues F4.43, L4.44, I4.47, and A4.48 of 5-HT2A, which are 
oriented facing the lipid bilayer, play a critical role in the expression of the heteromeric complex 
with mGlu2 in HEK-293 cells. Replacing these four residues with those in the TM4 of the 
closely similar 5-HT2C significantly disrupts its heteromeric association with the 5-HT2A 
receptor (Fig. 3A). Functional and structural assays performed in this study verify the expression 
of the 5-HT2A-TM4ΔNF is homologous to 5-HT2A; therefore, the reduced signal observed in the 
co-immunoprecipitation immunoblot assay can be attributed to a disruption in the heteromeric 
association rather than a decrease in the level of expression. It should be noted, the sample size 
used in this study was relatively small (n=3). Nevertheless, these findings suggest that N-
terminal residues are critical structural components mediating heteromeric formation. It is 
important to mention the present evidence does not exclude the possibility other residues not in 
the N-terminal half of TM4 still maintain the heteromeric interface. It is also possible 5-
HT2A and mGlu2 receptors interact indirectly as a part of a larger protein complex, by way-of 
scaffolding proteins, rather than interacting directly as a part of a GPCR heteromeric complex. 
To verify the overall quaternary structure of the receptor had not been disrupted with the 
introduction of 5-HT2C residues, Western blot assays were performed. This confirmed structure 
and expression of 5-HT2A-TM4ΔNF was homologous to 5-HT2A. While two anti-myc 
immunoreactive bands were detected, statistical analysis was performed only on the 250 kDa 
(pentamer) signal. This was due to the co-immunoprecipitated immunoblot assay revealing no 




Cross-talk plays a critical role in forming a Gi/Gq balance between the 5-HT2A and mGlu2 
receptors. Therefore, when characterizing the 5-HT2A-TM4ΔNF mutant chimera, it was 
necessary to confirm the mutation did not cause dysfunctionality in signaling. Ca2+ mobilization 
confirmed that the 5-HT2A-TM4ΔNF mutant forms a functional receptor that is functionally 
homologous to WT 5-HT2A. Further cross-talk studies, as described in Moreno et al. (2016), 
could be used to verify the disruption of the heteromeric complex observed in the co-
immunoprecipitation (Fig. 3). A failure or reduction in the Ca2+ signal induced by activation of 
the mGlu2 receptor would confirm the results observed in this study, suggesting the heteromeric 
interface has been disrupted significantly.  
A potential explanation for the reduced signal detected in this study could be the 5-HT2A-
TM4ΔNF receptor does not properly get trafficked into the membrane, and therefore does not 
form an interaction with mGlu2. This possibility was investigated using confocal fluorescence 
microscopy, verifying the 2A/2C chimera showed proper subcellular localization following 
translation. mCherry fluorescence was detected predominantly in the plasma membrane, with 
other signals detected in unidentified cellular compartment(s). Before being trafficked into the 
plasma membrane, 5-HT2A plasmids are first translated in the endoplasmic reticulum (ER). 
Therefore, the concentrated fluorescence not surrounding the cell is likely localized in the ER. 
To verify this, immunocytochemistry can be performed staining for an ER-resident protein (e.g., 
calreticulin) and the 5-HT2A-TM4ΔNF receptor.  
It would also be interesting to image 5-HT2A-TM4ΔNF co-transfected with mGlu2 to verify the 





This study utilized human embryonic kidney cells (HEK-293) as a heterologous expression 
system, as it allows for highly reproducible results and maintains consistency with previous 
studies investigating the 5-HT2A·mGlu2 complex in vitro (Moreno et al., 2012; Gonzalez-Maeso 
et al., 2008; Thibado et al., 2021). It is appropriate to recognize a potential limitation when using 
HEK-293 cells as an expression system. When cells are cultured for an extended period of time, 
their health deteriorates. This has an effect on the cell’s growth rate and translation efficiency, 
which might have a negative effect on the overall study, including the repeatability of results 
(Thomas et al., 2005; Dumont et al., 2016). With this in mind, the maximum passage number 
was kept below 20 throughout this study. 
The main limitation of this study is the relatively small number of assays used to verify a 
disruption in the heterocomplex. In terms of future research, it would be interesting to confirm 
the current findings with biophysical assays such as BRET and FRET (Moreno et al., 2016). It 
should be noted these methods most commonly used to assess GPCR homo- or hetero-
dimerization, including co-immunoprecipitation, cannot demonstrate direct physical proximity 
between two receptors. Protein to protein interactions detected by these techniques could instead 
be facilitated by a third unknown protein that associates all the proteins into a larger complex, 
rather than being in direct physical proximity between the two receptors. 
Much work remains to be done before a complete understanding of the 5-HT2A·mGlu2 
heteromeric interface is established. While this study provides valuable information on TM4 
residues implicated in heteromer formation, alone, it does not provide sufficient evidence to 
confirm the residues mutated in the 5-HT2A-TM4ΔNF form a direct interaction with mGlu2. As 
the co-immunoprecipitation assay revealed a significant reduction in immunoreactivity but not 




terminal end of TM4 that also mediate the formation of the 5-HT2A·mGlu2 complex. Therefore, 
other constructs mutating non-homologous residues in the C-terminal half of TM4 could be 
created and co-immunoprecipitated with mGlu2 to determine whether other residues also play a 
role in mediating the heteromeric interface. It could also be possible not all four mutations found 
in 5-HT2A-TM4ΔNF are necessary to disrupt the dimeric interface. This may be addressed by 
introducing single point mutations of F4.43, L4.44, A4.47, and I4.48 to create four separate 
constructs to determine whether one of these residues alone produces a significant disruption in 
the co-immunoprecipitation signal. While the 5-HT2A-TM4ΔNF construct mutated four residues 
in the N terminal half of TM4, it is possible even a partial mutant, where only two residues were 
mutated (e.g., I4.47 and A4.48), could be sufficient in disrupting the binding interface of the 
heteromer. 
As 5-HT2C does not form a heterocomplex with mGlu2, it would also be interesting to introduce 
the 5-HT2A receptor residues (F4.43, L4.44, A4.47, and I4.48) into the 5-HT2C receptor to try to 
revive dimerization. This would provide further evidence for these residues' role in mediating the 
heteromeric interface. 
While commonly used methods to assess GPCR homo/heteromerization are mostly indirect 
approaches, a photocrosslinking technique can identify individual amino acids that interact 
physically at the heteromeric interface without compromising the overall structural integrity of 
either protomer in the complex (Shah et al., 2020). For example, four new constructs correspond 
to the four residues used to create the 5-HT2A-TM4NF construct, could be refined to include a 
single photoreactive unnatural amino acid corresponding to F4.43, L4.44, A4.47, or I4.48 
corresponding to each of the four new constructs. These constructs could then undergo UV-




this study form a direct interaction with mGlu2 and participate directly in establishing the 
heteromeric interface of the 5-HT2A-mGlu2 complex. 
Although the current results must be verified by future research, the present study has provided 
clear evidence for the involvement of the N-terminal end of TM4 of the 5-HT2A receptor in its 
heteromeric assembly with the mGlu2 receptor and provides a good starting point for further 
studies.  
Conclusion: 
• Sequence analysis of 5-HT2A-ΔTM4NF verifies the construct contains the 5-HT2C 
receptor residues located at the N-terminal of the TM4. 
• Immunoblot experiments conducted in this study verify the similar expression of 5-HT2A-
ΔTM4NF and WT 5-HT2A  
• 5-HT2A-TM4NF/mGlu2 co-immunoprecipitation was significantly reduced, suggesting 
the heteromeric interface had been disrupted. 
• Functional homology was verified through Ca2+ mobilization, displaying a similar pattern 
of Ca2+ release between the 5-HT2A-ΔTM4NF and WT 5-HT2A 
• [3H]ketanserin binding confirmed receptor density and affinity similarity between 5-
HT2A-TM4NF and WT 5-HT2A. 
• Cytochemistry confirmed the 5-HT2A-ΔTM4NF mutant has proper subcellular 
localization. 
• Further analysis to confirm the findings includes BRET, FRET, and fluorescent 




• Future work in using a photocrosslinking technique to identify the individual residues 
responsible for the heteromeric interface 
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